Emergent BioSolutions Inc (EBS)
2.16
-0.13
(-5.68%)
USD |
NYSE |
Apr 24, 14:08
Emergent BioSolutions Cash from Operations (TTM): -206.30M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -206.30M |
September 30, 2023 | -145.60M |
June 30, 2023 | -279.60M |
March 31, 2023 | -180.80M |
December 31, 2022 | -34.10M |
September 30, 2022 | 201.20M |
June 30, 2022 | 291.90M |
March 31, 2022 | 277.80M |
December 31, 2021 | 320.20M |
September 30, 2021 | 238.10M |
June 30, 2021 | 326.60M |
March 31, 2021 | 484.20M |
December 31, 2020 | 536.90M |
September 30, 2020 | 413.00M |
June 30, 2020 | 304.70M |
March 31, 2020 | 141.00M |
December 31, 2019 | 188.00M |
September 30, 2019 | -99.90M |
June 30, 2019 | 77.20M |
March 31, 2019 | 147.60M |
December 31, 2018 | 41.80M |
September 30, 2018 | 285.09M |
June 30, 2018 | 146.03M |
March 31, 2018 | 165.43M |
December 31, 2017 | 208.10M |
Date | Value |
---|---|
September 30, 2017 | 117.96M |
June 30, 2017 | 110.10M |
March 31, 2017 | 54.10M |
December 31, 2016 | 54.60M |
September 30, 2016 | 68.38M |
June 30, 2016 | 146.06M |
March 31, 2016 | 150.56M |
December 31, 2015 | 42.52M |
September 30, 2015 | 93.21M |
June 30, 2015 | 67.37M |
March 31, 2015 | 75.69M |
December 31, 2014 | 112.32M |
September 30, 2014 | 69.14M |
June 30, 2014 | 50.34M |
March 31, 2014 | 72.35M |
December 31, 2013 | 96.97M |
September 30, 2013 | 49.31M |
June 30, 2013 | 35.67M |
March 31, 2013 | 21.18M |
December 31, 2012 | 39.64M |
September 30, 2012 | 115.59M |
June 30, 2012 | 73.77M |
March 31, 2012 | 48.75M |
December 31, 2011 | 12.18M |
September 30, 2011 | -2.09M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-279.60M
Minimum
Jun 2023
536.90M
Maximum
Dec 2020
150.24M
Average
201.20M
Median
Sep 2022
Cash from Operations (TTM) Benchmarks
Avid Bioservices Inc | 1.705M |
Viking Therapeutics Inc | -73.38M |
FibroGen Inc | -315.02M |
Avinger Inc | -14.43M |
RAPT Therapeutics Inc | -97.05M |